Greater US FDA And Manufacturer Transparency Recommended As Key to Supply Chain Resilience

Manufacturers could risk losing FDA product approvals if they fail to publicize sourcing and quality information, under new proposals. National Academies expert panel says supply chain transparency – not a pandemic-induced rush to onshoring requirements  –  provides the framework to mitigate against and respond to drug shortages.